| payload |
{"created_at":"2026-04-06T21:04:57.701 {"created_at":"2026-04-06T21:04:57.701497+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:0dba1520b5d718a7","evidence_event_ids":["evt_3108f6db04c6"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/why-soleno-therapeutics-stock-rocketed-higher-monday","as_of":"2026-04-06T21:04:57.701497+00:00","canonical_url":"https://www.fool.com/investing/2026/04/06/why-soleno-therapeutics-stock-rocketed-higher-on-m/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/why-soleno-therapeutics-stock-rocketed-higher-monday","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_3e2d4f940175b1a8","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/06/why-soleno-therapeutics-stock-rocketed-higher-on-m/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-07T14:52:24.327899+00:00","extraction_method":"heuristic","fetched_description":"Key PointsThe deal isn't cheap; the biotech is changing hands at a 34% premium.","fetched_title":"Why Soleno Therapeutics Stock Rocketed Higher on Monday | Nasdaq","final_url":"https://www.nasdaq.com/articles/why-soleno-therapeutics-stock-rocketed-higher-monday","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/why-soleno-therapeutics-stock-rocketed-higher-monday","source_event_id":"evt_3108f6db04c6","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"c99eee567f302b17","kind":"unusual_volume","published_at":"2026-04-06T20:40:38+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.95,"dates_mentioned":["April 06, 2026"],"entities":[{"asset_class":"equity","name":"Soleno Therapeutics","relevance":"acquired company","symbol":"SLNO","type":"company"},{"asset_class":"equity","name":"Neurocrine Biosciences","relevance":"acquiring company","symbol":"NBIX","type":"company"}],"event_type":"merger_acquisition","information_gaps":["Exact volume ratio vs average volume is not provided.","Baseline volume data is missing."],"key_facts":["Soleno's stock gained 32% on the day of the acquisition announcement.","The acquisition deal is valued at $2.9 billion, with Neurocrine paying $53 per share.","The acquisition is subject to the tender of at least a majority of Soleno's outstanding shares."],"numeric_claims":[{"label":"premium on acquisition","value":"34%"},{"label":"stock gain on announcement","value":"32%"}],"primary_claim":"Soleno Therapeutics stock rose 32% following the announcement of its acquisition by Neurocrine Biosciences.","relevance_score":0.9,"sentiment":"positive","source_quality":"high","summary":"Soleno Therapeutics (NASDAQ: SLNO) experienced a significant stock increase due to its acquisition by Neurocrine Biosciences (NASDAQ: NBIX) at a 34% premium, valued at $2.9 billion.","topics":["mergers","acquisitions","biotech","stock market"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsThe deal isn't cheap; the biotech is changing hands at a 34% premium.","tickers":[],"title":"Why Soleno Therapeutics Stock Rocketed Higher on Monday","url":"https://www.fool.com/investing/2026/04/06/why-soleno-therapeutics-stock-rocketed-higher-on-m/"}}... |